The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
8,499
Sort by:
Nonstructural Protein 1 (NS1) - Drugs in Development, 2021
US$ 3,000.00
Nonstructural Protein 1 (NS1) - Drugs in Development, 2021 SUMMARY Nonstructural Protein 1 (NS1) - Drugs in Development, 2021 provides in depth analysis on Nonstructural Protein 1 (NS1) targeted pipel...
April 2021
35 pages
Nonstructural Protein 3 (NS3) - Drugs in Development, 2021
US$ 3,000.00
Nonstructural Protein 3 (NS3) - Drugs in Development, 2021 SUMMARY Nonstructural Protein 3 (NS3) - Drugs in Development, 2021 provides in depth analysis on Nonstructural Protein 3 (NS3) targeted pipel...
April 2021
30 pages
Ocular Melanoma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Ocular Melanoma (Oncology) - Drugs in Development, 2021 SUMMARY Ocular Melanoma (Oncology) - Drugs in Development, 2021 provides an overview of the Ocular Melanoma pipeline landscape. The report provi...
April 2021
40 pages
Opioid Receptor (OPR) - Drugs in Development, 2021
US$ 3,000.00
Opioid Receptor (OPR) - Drugs in Development, 2021 SUMMARY Opioid Receptor (OPR) - Drugs in Development, 2021 provides in depth analysis on Opioid Receptor (OPR) targeted pipeline therapeutics. The re...
April 2021
40 pages
p38 MAP Kinase (EC 2.7.11.24) - Drugs in Development, 2021
US$ 3,000.00
p38 MAP Kinase (EC 2.7.11.24) - Drugs in Development, 2021 SUMMARY p38 MAP Kinase (EC 2.7.11.24) - Drugs in Development, 2021 provides in depth analysis on p38 MAP Kinase (EC 2.7.11.24) targeted pipel...
April 2021
50 pages
Papillary Tumor (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Papillary Tumor (Oncology) - Drugs in Development, 2021 SUMMARY Papillary Tumor (Oncology) - Drugs in Development, 2021 provides an overview of the Papillary Tumor pipeline landscape. The report provi...
April 2021
30 pages
